Diagnosing amyloidosis typically requires a combination of blood tests, tissue biopsy with specialized staining, and imaging, followed by precise identification of the amyloid type. No single test confirms the diagnosis on its own. The process moves through several layers: detecting that something is wrong, proving amyloid protein is present in tissue, and then determining exactly which type of amyloid it is, since treatment depends entirely on that answer.
Blood and Urine Screening
The diagnostic workup usually begins with blood and urine tests that look for abnormal proteins. For AL amyloidosis, the most common systemic form, a serum free light chain assay is one of the most important initial tests. This measures fragments of antibodies (called light chains) circulating in your blood. A normal ratio of the two types of light chains (kappa and lambda) falls between 0.26 and 1.65. In AL amyloidosis, this ratio is abnormal in about 88% of patients, making it a reliable early signal.
Doctors will also order serum protein electrophoresis and immunofixation electrophoresis on both blood and urine samples. These tests detect monoclonal proteins, the abnormal proteins produced by a single clone of plasma cells. Together with the free light chain assay, this panel catches nearly all cases of AL amyloidosis at the screening stage.
Kidney involvement is common, appearing in 50 to 70% of AL amyloidosis patients at diagnosis. It shows up as excess protein spilling into the urine, defined as more than 0.5 grams per day on a 24-hour urine collection. A simpler spot urine test (the albumin-to-creatinine ratio) can reliably estimate this: a value above 300 mg/g predicts significant proteinuria with 92% sensitivity and 97% specificity, potentially sparing patients the inconvenience of collecting urine for a full day.
Tissue Biopsy and Congo Red Staining
A definitive amyloidosis diagnosis requires proof that amyloid protein has deposited in tissue. The standard method is a biopsy stained with Congo red dye, which makes amyloid deposits glow apple-green under polarized light. This remains the diagnostic gold standard.
The most common first biopsy is a fat pad aspiration, a simple procedure where a needle draws a small sample of fat from the belly. It’s low-risk, inexpensive, and widely available. For AL amyloidosis, this test picks up amyloid deposits in about 84% of cases. Sensitivity rises with the amount of amyloid in the body: patients with a large amyloid burden are detected 100% of the time, while those with a small burden are caught about 78% of the time.
For other types of amyloidosis, the fat pad biopsy is far less reliable. It detects amyloid in only 45% of patients with hereditary ATTR amyloidosis and just 15% of patients with wild-type ATTR (the age-related form that primarily affects the heart). When the fat pad comes back negative but suspicion remains high, doctors proceed to a biopsy of the affected organ itself, such as the heart, kidney, or liver. A bone marrow biopsy is also commonly performed alongside the fat pad sample, since the combination of both improves overall detection.
Identifying the Amyloid Type
Confirming that amyloid is present is only half the battle. The specific protein forming the deposits must be identified, because AL amyloidosis requires chemotherapy targeting abnormal plasma cells, while ATTR amyloidosis is treated with drugs that stabilize or silence the transthyretin protein. Getting this wrong can be dangerous.
Older methods rely on antibody-based staining (immunohistochemistry), where antibodies are applied to the tissue sample to see which amyloid protein they stick to. This approach has significant limitations. Standard antibody panels only test for three amyloid types and can miss rare forms entirely. The tightly folded structure of amyloid fibrils also causes antibodies to stick nonspecifically, producing misleading results.
Mass spectrometry has become the preferred method at specialized centers. It breaks down the proteins in the tissue sample and identifies them by their molecular fingerprints, recognizing all amyloid types in a single test. It also reliably detects mutant and truncated protein forms that antibody-based methods frequently miss. If your biopsy is being analyzed at a center without mass spectrometry capability, it may be worth asking about sending the sample to a reference laboratory.
The Bone Scan That Can Replace a Heart Biopsy
For suspected ATTR cardiac amyloidosis, a nuclear bone scan (called a PYP scan, DPD scan, or HMDP scan depending on your country) has transformed the diagnostic process. The scan uses a radioactive tracer originally designed to image bones. In ATTR amyloidosis, the tracer binds strongly to amyloid deposits in the heart muscle.
Results are graded on a simple scale. Grade 0 means no tracer uptake in the heart (negative). Grade 1 is inconclusive. Grades 2 and 3, where the heart lights up as brightly as or more brightly than the ribs, are considered positive for ATTR amyloidosis. Before this scan existed, a heart biopsy was the only way to distinguish ATTR from AL amyloidosis in the heart. Now, when the scan shows grade 2 or 3 uptake and blood tests rule out a monoclonal protein (which would suggest AL), the diagnosis of ATTR cardiac amyloidosis can be made without any heart biopsy at all.
This scan does not detect AL amyloidosis. A negative result in someone with heart failure and abnormal light chains in their blood actually points toward AL as the more likely diagnosis.
Cardiac MRI for Assessing Heart Involvement
Cardiac MRI provides detailed information about how much amyloid has infiltrated the heart, even though it doesn’t replace the need for a type-specific diagnosis. After a contrast agent is injected, healthy heart muscle and blood follow a predictable pattern of signal behavior. In cardiac amyloidosis, this relationship is reversed: the heart muscle reaches its signal null point before the blood pool does, which is a hallmark finding.
The enhancement pattern in amyloidosis is typically diffuse and irregular, often concentrated in the inner layer of the heart wall. This looks different from the patchy scarring seen in conditions like a heart attack or myocarditis, helping to narrow the differential diagnosis. Cardiac MRI also measures the extracellular volume of the heart, which reflects how much space amyloid protein occupies between heart muscle cells. This measurement tracks disease severity and can be used to monitor response to treatment over time.
Genetic Testing for Hereditary Forms
When ATTR amyloidosis is diagnosed, genetic testing of the TTR gene determines whether the disease is hereditary or wild-type (age-related). This distinction matters for treatment planning and has major implications for family members.
The most common mutation worldwide, Val50Met, appears in large clusters in Portugal, Sweden, and Japan. In the United States, the Val142Ile variant is carried by 3 to 4% of African Americans, and most people with this mutation eventually develop late-onset cardiac amyloidosis. In parts of West Africa, more than 5% of the population carries this variant. If a hereditary mutation is found, at-risk family members can undergo predictive testing to determine whether they carry the same variant, allowing early monitoring and treatment before symptoms develop.
Staging After Diagnosis
Once the type of amyloidosis is confirmed, staging determines how advanced the disease is, primarily by measuring heart involvement. For AL amyloidosis, the staging system uses two cardiac biomarkers drawn from a standard blood test: NT-proBNP (a marker of heart strain) and high-sensitivity troponin T (a marker of heart muscle damage).
Stage I means both markers are below their thresholds, indicating minimal cardiac involvement and the best prognosis. Stage II means one marker is elevated. Stage III, where both are elevated, is subdivided further. The highest risk category, Stage IIIC, combines very high levels of both biomarkers with severely impaired heart function measured by strain imaging on echocardiography. These stages directly guide how aggressively treatment is pursued and help set realistic expectations about outcomes.
Ruling Out Look-Alike Conditions
One of the trickiest parts of diagnosing amyloidosis is that many patients with ATTR amyloidosis also have a benign condition called MGUS, where a small amount of abnormal protein circulates in the blood without causing harm. About 5% of people over 70 have MGUS, and since ATTR amyloidosis also tends to appear in older adults, the two frequently overlap. If a doctor sees abnormal light chains alongside a positive bone scan, they might mistakenly diagnose AL amyloidosis when the patient actually has ATTR.
The key to distinguishing them is demonstrating that organ damage is directly caused by the monoclonal protein. This requires showing that the amyloid deposits themselves contain monoclonal light chain, not just that a monoclonal protein exists in the blood. Careful evaluation of organ function through physical exam, lab work, and, when needed, mass spectrometry typing of the biopsy tissue prevents this potentially dangerous misclassification.